Top Markets
Coin of the day
OmniAb, Inc. OmniAb, Inc.

OmniAb, Inc.

OABI
Kedudukan dalam Saham #11865
OmniAb, Inc. is an American biotechnology firm focused on pioneering... OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Harga Saham
$4.48
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$649.33M
Perubahan (1 hari)
-2.84%
Perubahan (1 tahun)
179.94%
Negara
US
Perdagangan OmniAb, Inc. (OABI)

Kategori

Bilangan saham terbitan bagi OmniAb, Inc. (OABI)
Bilangan saham terbitan setakat August 2026: 0
Menurut laporan kewangan terkini dan harga saham OmniAb, Inc., bilangan saham terbitan semasa ialah 0. Pada akhir August 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk OmniAb, Inc. (OABI) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M -
US
62.19M -
NL
478.91M -
AU
396.00M -
US
- -
CH